By: IPP Bureau
Last updated : December 26, 2025 1:15 pm
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Global pharma giant Cipla has announced the launch of Afrezza (insulin human) inhalation powder in India, offering a rapid-acting, needle-free alternative to traditional injectable insulin.
The product, approved last year by the Central Drugs Standard Control Organisation (CDSCO), targets the 10 crore adults currently living with diabetes mellitus in India.
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge.
Typically started with the largest meal of the day, the dosage can be intensified as needed. Developed and manufactured by MannKind Corporation (USA), Afrezza dissolves instantly in the lungs and begins lowering blood glucose in just 12 minutes, closely mimicking the body’s natural insulin response.
By providing a needle-free, rapid-acting alternative, Afrezza aims to improve treatment adherence and enable quicker glycemic control for adults with both type 1 and type 2 diabetes. The innovative delivery system also addresses the emotional and practical barriers that often cause patients to delay or stop insulin therapy—a critical need highlighted by healthcare experts.
Commenting on the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: "At Cipla, our purpose has always been simple – to make quality healthcare more accessible for every patient. The introduction of Afrezza in India reflects that responsibility. This innovation not only simplifies insulin delivery but also eases many of the emotional and practical barriers patients face with daily insulin injections.
"With our reach and our deep commitment to patient well-being, we hope to support millions of Indians in managing their diabetes with greater confidence and comfort."
In addition, Cipla is rolling out a nationwide awareness campaign to tackle the emotional and behavioral barriers that hinder insulin adherence. The initiative will address fears around injections, complex treatment routines, and social stigma, using empathetic storytelling and structured patient-support programs.